A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants
INT22854
Phase 1 other active
Quick answer
A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants for Immune Thrombocytopenia Purpura is a Phase 1 program (other) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Immune Thrombocytopenia Purpura
- Phase
- Phase 1
- Modality
- other
- Status
- active